[go: up one dir, main page]

WO2007058991A3 - Mutations et polymorphismes de c-abl - Google Patents

Mutations et polymorphismes de c-abl Download PDF

Info

Publication number
WO2007058991A3
WO2007058991A3 PCT/US2006/043898 US2006043898W WO2007058991A3 WO 2007058991 A3 WO2007058991 A3 WO 2007058991A3 US 2006043898 W US2006043898 W US 2006043898W WO 2007058991 A3 WO2007058991 A3 WO 2007058991A3
Authority
WO
WIPO (PCT)
Prior art keywords
abl
mutations
polymorphisms
mutant
various aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/043898
Other languages
English (en)
Other versions
WO2007058991A2 (fr
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007058991A2 publication Critical patent/WO2007058991A2/fr
Publication of WO2007058991A3 publication Critical patent/WO2007058991A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne en général l'analyse d'échantillons tissulaires in vitro et, en particulier, des aspects de polymorphismes et de mutations génétiques du gène c ABL. L'invention concerne également de nouvelles mutations de c ABL et des polymorphismes nucléotidiques simples (SNP) utilisés pour effectuer un diagnostic ou traiter des sujets qui en ont besoin. En conséquence, les différents aspects de l'invention concernent des polynucléotides codant pour les mutations de c ABL, des vecteurs d'expression codant pour les polypeptides mutants de c ABL, des organismes qui expriment le mutant de c ABL, des polynucléotides polymorphiques et/ou des polypeptides mutants/polymorphiques de c ABL. Les différents aspects de l'invention concernent également des méthodes diagnostiques/théranostiques et des trousses qui utilisent les mutations et les polymorphismes de c ABL pour identifier les individus prédisposés à une maladie ou pour classer des individus en fonction de leur sensibilité à un médicament, des effets secondaires ou d'une dose de médicament optimale.
PCT/US2006/043898 2005-11-14 2006-11-13 Mutations et polymorphismes de c-abl Ceased WO2007058991A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73659205P 2005-11-14 2005-11-14
US60/736,592 2005-11-14

Publications (2)

Publication Number Publication Date
WO2007058991A2 WO2007058991A2 (fr) 2007-05-24
WO2007058991A3 true WO2007058991A3 (fr) 2007-09-07

Family

ID=37947462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043898 Ceased WO2007058991A2 (fr) 2005-11-14 2006-11-13 Mutations et polymorphismes de c-abl

Country Status (1)

Country Link
WO (1) WO2007058991A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (fr) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations dans la tyrosine kinase bcr-abl associees a la resistance a sti-571
WO2003031608A2 (fr) * 2001-10-05 2003-04-17 Novartis Ag Domaines de l'abl kinase mutes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (fr) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations dans la tyrosine kinase bcr-abl associees a la resistance a sti-571
WO2003031608A2 (fr) * 2001-10-05 2003-04-17 Novartis Ag Domaines de l'abl kinase mutes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 1418, ISSN: 0006-4971 *
CAZZANIGA GIOVANNI ET AL: "Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 548A, XP009084661, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), SHAH NEIL P ET AL: "Relapse of Chronic Phase Chronic Myeloid Leukemia (CML) on Imatinib: BCR-ABL Kinase Domain Mutations Conferring Drug Resistance Are Frequently Detectable Prior to Clinical Evidence of Relapse.", XP002436233, Database accession no. PREV200300336018 *
JABBOUR ELIAS ET AL: "Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 288A, XP009084663, ISSN: 0006-4971 *
MANLEY ET AL: "Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1754, no. 1-2, 8 September 2005 (2005-09-08), online, pages 3 - 13, XP005214189, ISSN: 1570-9639 *
VON BUBNOFF NIKOLAS ET AL: "BCR-ABL RESISTANCE SCREENING PREDICTS A LIMITED SPECTRUM OF POINT MUTATIONS TO BE ASSOCIATED WITH CLINICAL RESISTANCE TO THE ABL KINASE INHIBITOR NILOTINIB (AMN107)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 108, no. 4, 15 August 2006 (2006-08-15), pages 1328 - 1333, XP009082063, ISSN: 0006-4971 *
WILLIS STEPHANIE G ET AL: "High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy", BLOOD, vol. 106, no. 6, September 2005 (2005-09-01), pages 2128 - 2137, XP002436225, ISSN: 0006-4971 *
WULFKUHLE J ET AL: "Genomic and proteomic technologies for individualisation and improvement of cancer treatment", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 40, no. 17, November 2004 (2004-11-01), pages 2623 - 2632, XP004646472, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
WO2007058991A2 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007016532A3 (fr) Mutations et polymorphismes de hdac4
WO2009132058A3 (fr) Niveaux d’expression de la protéine bcma sur les lymphocytes b et utilisation dans de méthodes diagnostiques
WO2002086448A3 (fr) Detection de l'instabilite des microsatellites et son utilisation dans le diagnostic des tumeurs
WO2005033652A3 (fr) Procedes pour comparer des debits relatifs d'au moins deux molecules biologiques in vivo dans un protocole simple
EP2896703A3 (fr) Mutations du gène PIK3CA dans les cancers humains
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2006127861A3 (fr) Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
WO2002022879A3 (fr) Detection de l'instabilite des microsatellites et utilisation de celle-ci dans le diagnostic de tumeurs
WO2006105252A3 (fr) Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
WO2005082042A3 (fr) Methodes therapeutiques faisant appel a des precurseurs d'oxyde nitrique
WO2006130527A3 (fr) Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes
WO2006110478A3 (fr) Mutations et polymorphismes du recepteur du facteur de croissance epidermique
WO2007022041A3 (fr) Mutations et polymorphismes de l'hdac3
EP2287340A3 (fr) Procédé de diagnostic et traitement d'une maladie mentale
WO2007030455A3 (fr) Mutations et polymorphismes de hdac10
WO2005015155A3 (fr) Methodes de comparaison des debits relatifs d'au moins deux molecules biologiques in vivo au moyen d'un seul protocole
WO2007038073A3 (fr) Mutations et polymorphismes de l’hdac11
WO2007030454A3 (fr) Mutations et polymorphismes de hdac9
WO2007058992A3 (fr) Mutations et polymorphismes de hdac6
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
WO2007109183A3 (fr) Mutations et polymorphismes de la tyrosine kinase 1 liée au fms
WO2006081248A3 (fr) Marqueurs du cancer et procedes de detection
WO2007047998A3 (fr) Mutations et polymorphismes du gène de l'hdac2
WO2004113574A3 (fr) Methodes de depistage d'une maladie
WO2007095032A3 (fr) Mutations et polymorphismes du gène ptk2b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837390

Country of ref document: EP

Kind code of ref document: A2